1259P - Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma
| Autor: | Reijers, I.L.M., Rozeman, E.A., Mallo, H., Uyterlinde, W., Adriaansz, S., Lijnsvelt, J., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|